Prostate cancer trials recruiting in Georgia

All Prostate cancer trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
  NCT06785636 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06842498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Newnan
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Newnan
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Athens
• Addressing Health Literacy With a Tailored Survivorship Care Plan
  NCT06674863 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
  NCT06865768 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
  NCT07206056 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Georgia: Atlanta
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
  NCT05413850 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
  NCT04038502 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Decatur
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Georgia: Braselton, Decatur, Gainesville, Savannah
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta, Decatur, Johns Creek
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
  NCT07080242 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
  NCT06262139 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · Georgia: Atlanta
• High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
  NCT05011383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Decatur
• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
  NCT07569926 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• Improving Health Literacy in African-American Prostate Cancer Patients
  NCT03322891 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 100 Years · Sex: Male · Georgia: Atlanta
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Georgia: Atlanta
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
  NCT05803941 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: Male · Georgia: Athens
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Georgia: Athens, Atlanta
• Prostate Active Surveillance Study
  NCT00756665 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Georgia: Atlanta
• Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
  NCT04725903 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
  NCT06650579 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
  NCT01885299 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Georgia: Brunswick
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Georgia: Atlanta, Savannah
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
  NCT06582017 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta, Augusta, Decatur
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
  NCT06855277 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Georgia: Athens
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• Study of AZD0754 in Participants With Metastatic Prostate Cancer
  NCT06267729 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: Male · Georgia: Atlanta
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
  NCT07288359 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
  NCT05586360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Newnan
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta, Decatur
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Atlanta, Duluth, Lawrenceville
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Johns Creek
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Georgia: Dalton, Ringgold
• Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
  NCT06651359 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Georgia: Milledgeville
• cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
  NCT05366881 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Georgia: Gainesville